This article is more than 5 years old. Information may no longer be current.

Eyenovia enrolling broad patient population in MicroProst phase 3 trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Eyenovia will include a broad patient population, including patients with chronic angle closure glaucoma, open-angle glaucoma and ocular hypertension, in a phase 3 trial of MicroProst, according to a press release.

MicroProst (microdose latanoprost with Optejet delivery) uses Eyenovia’s piezo-print delivery technology to deliver microdoses of IOP-lowering medications.

“If approved, MicroProst could have one of the widest indications of commercially available IOP-lowering therapies, as well as represent the first FDA-approved drug specifically indicated for chronic angle closure glaucoma,” Sean Ianchulev, MD, MPH, Eyenovia CEO and chief medical officer, said in the release. “Based on the results of our earlier phase 2 trial for IOP lowering, we believe that MicroProst may achieve similar clinical efficacy with improved tolerability vs. latanoprost administered in drop form, which can overdose the eye with potentially harmful preservatives and active ingredient.”